Search information pages
About Clinical Proteomics
This page includes information about the aims and scope of Clinical Proteomics, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.
Aims & scope
Clinical Proteomics encompasses all aspects of translational proteomics. Special emphasis will be placed on the application of proteomic technology to all aspects of clinical research and molecular medicine. The journal is committed to rapid scientific review and timely publication of submitted manuscripts.
A key feature of Clinical Proteomics is its commitment to rapid scientific review and timely publication of submitted manuscripts. This is achieved receiving and processing submissions online. As molecular medicine moves beyond genomics to proteomics, the goal becomes the characterization of the cellular circuitry and the understanding of the impact of disease and therapy on cellular networks. Clinical Proteomics provides a scholarly forum for novel scientific research in the field of translational proteomics. The journal places special emphasis on the application of proteomic technology to all aspects of clinical research. A key feature is its commitment to rapid scientific review and timely publication of submitted manuscripts.
All articles published by Clinical Proteomics are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
Authors of articles published in Clinical Proteomics are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.
For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Clinical Proteomics therefore levies an article-processing charge of £1290/$2110/€1550 for each article accepted for publication. We routinely waive charges for authors from low-income countries. Generally, if the submitting author's institution is a Member the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. For further details, see our article-processing charge page. A limited number of waivers for article-processing charges are also available at the editors' discretion, and authors wishing to apply for these waivers should contact the editors.
All articles published in Clinical Proteomics are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in Clinical Proteomics include:
- Google Scholar
- Summon by Serial Solutions
The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives including e-Depot (The Netherlands).
Clinical Proteomics has an unofficial Impact Factor of 3.0. BioMed Central is working with Thomson Reuters (ISI) to ensure that citation analysis of articles published in Clinical Proteomics will be available.
Publication and peer review process
Clinical Proteomics considers the types of articles.
- Research: reports of data from original research.
- Reviews: comprehensive, authoritative, descriptions of any subject within the scope of the journal. These articles are usually written by opinion leaders that have been invited by the Editorial Board.
- Letters to the Editor: these can take three forms: a substantial re-analysis of a previously published article, or a substantial response to such a re-analysis from the authors of the original publication, or an article that may not cover 'standard research' but that may be relevant to readers.
Manuscripts will be assigned to a Monitoring Editor, who will appoint at least two referees. On receipt of their reports the Monitoring Editor will make a recommendation to accept, to accept with minor revisions, to request major revisions and resubmission, or to reject. No manuscript will be rejected without being assessed by a member of the Editorial Board and one other expert.
Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Clinical Proteomics, a personalized section of the site.
High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.
Clinical Proteomics will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.
All manuscripts submitted to Clinical Proteomics should adhere to BioMed Central's editorial policies.
Citing articles in Clinical Proteomics
Articles in Clinical Proteomics should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Clin Proteomics [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Clin Proteomics 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Why publish your article in Clinical Proteomics?
Clinical Proteomics's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.
Speed of publication
Clinical Proteomics offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles are published with their final citation immediately upon acceptance in a provisional PDF form. The article will subsequently be published in both fully browsable web form, and as a formatted PDF; the article will then be available through Clinical Proteomics, BioMed Central and PubMed Central and will also be included in PubMed.
Online publication in Clinical Proteomics gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Clinical Proteomics are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Clinical Proteomics's pages and on the BioMed Central homepage.
In addition, articles published in Clinical Proteomics may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Clinical Proteomics. A list of articles recently press-released by journals published by BioMed Central is available here.
Authors of articles published in Clinical Proteomics retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright and license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.